scholarly journals Potential relation between non-alcoholic fatty liver disease and glycemic and metabolic parameters in subjects without diabetes

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
H. Naguib ◽  
H. Kassab
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Cutoff Point ◽  
Optimal Cutoff ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Optimal Cutoff Point ◽  
Hba1c Levels

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is proved to be related to insulin resistance and type 2 diabetes, and it is also not rare in individuals without diabetes. The present study attempts to identify the metabolic risk factors of NAFLD among those individuals. Results ALT and HbA1c levels were independently associated with NAFLD development in individuals without diabetes. Receiver operating characteristic (ROC) analysis identified the optimal cutoff point of ALT (> 19 IU/ml) with AUC = 0.731, 95% CI 0.653–0.809. On the other hand, the optimal cutoff point of HbA1c was identified to be > 5.1% with AUC = 0.665, 95% CI 0.581–0.750. Conclusions Early identification of NAFLD among subjects without diabetes is crucial. In this study, ALT and HbA1c cutoff values had been identified, so we suggest that inclusion of both HbA1c and ALT levels may have significant implications for prediction of NAFLD among individuals without diabetes.

scholarly journals Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
İlknur Ozturk Unsal ◽  
Murat Calapkulu ◽  
Muhammed Erkam Sencar ◽  
Basak Cakal ◽  
Mustafa Ozbek
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Diabetic Patients ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Control Blood Glucose ◽  
Obesity And Diabetes

AbstractThere is a closely relationship between the development and progression of nonalcoholic fatty liver disease (NAFLD) or metabolic associated fatty liver disease (MAFLD) and obesity and diabetes. NAFLD fibrosis scores should be routinely used to rule out patients with advanced fibrosis. High scores may help identify patients at higher risk of all causes andliverrelated morbidity and mortality. The aim of this study was to investigate the association between exenatide and fibrosis scores. The effect of exenatide treatment on fibrosis scores was evaluated in type 2 diabetes mellitus (DM) patients with MAFLD. Evaluation was made of 50 patients with type 2 DM and MAFLD. The NFS, FIB4 and APRI scores were calculated before and after 6 months of treatment. After 6 months of exenatide treatment, the NFS and APRI scores were determined to have decreased significantly. Exenatide was observed to control blood glucose, reduce body weight and improve fibrosis scores in MAFLD patients with type 2 diabetes.

scholarly journals Preliminary results of dulaglutide treatment in patients with non-alcoholic fatty liver disease (DEMOS study)

2020 ◽  
pp. 4-10
Author(s):  
P. O. Bogomolov ◽  
A. O. Bueverov ◽  
A. V. Dreval ◽  
O. A. Nechaeva ◽  
A. Yu. Mayorov ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Open Label ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Fatty Liver Index ◽  
Glucose And Lipid Metabolism ◽  
Alcoholic Fatty Liver Disease

65 patients with nonalcoholic fatty liver disease (NAFLD) were included in open-label observative prospective cohort study. Mean age was 54.8 ± 10.5 y. o. All patients were treated with metformin before and during the study. All patients were treated by GLP-1 receptor agonist dulaglutide subcutaneously weekly 26 weeks. Patients of group with type 2 diabetes were treated with dulaglutide 0.75 mg weekly 2 weeks, than 1.5 weekly 24 weeks. Patients of group without diabetes were treated by dulaglutide 0.75 mg weekly 4 weeks, than 1.5 weekly 22 weeks. Both groups of patients were demonstrated significant reduce of body weight, BMI, waist circumference, glucose, HbA1c, insulin resistance indexes, transaminases and gamma-glutamyltranspeptidase activity. Fatty liver index and liver stiff ness also decreased after treatment. We can conclude that dulaglutide treatment in NAFLD patients decreases body wieight, improves glucose and lipid metabolism and decreases inflammatory activity of steatohepatitis.

scholarly journals HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels

2020 ◽  
Vol 40 (1) ◽  
Author(s):  
Changxi Chen ◽  
Zhongwei Zhu ◽  
Yushan Mao ◽  
Yimin Xu ◽  
Juan Du ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Molecular Networks ◽  
Steady Increase ◽  
P Value ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
The Impact ◽  
Hba1c Levels

Abstract Previous clinical studies highlighted nonalcoholic fatty liver disease (NAFLD) as a hepatic facet of metabolic syndrome, which progresses toward Type 2 diabetes along with an elevation of HbA1c in the blood. Longitudinal observations were performed in a cohort of 2811 participants with no liver disease at inception. The rate of the conversion into NAFLD was 15.7% (440/2811), with a steady increase in prevalence observed in sub-cohorts with increasing HbA1c levels. Moreover, regression analysis indicated that HbA1c levels serve as the risk factors for NAFLD after multiple adjustments (odds ratio: 1.58, P-value < 0.004). When HbA1c-related molecular networks were investigated using natural language programming algorithms, multiple genetic/small molecular (SM) pathways were highlighted as connectors between the HbA1c levels and the development of NAFLD, including ones for nitric oxide, hypoxia and receptor for advanced glycation end products (RAGE). Our results suggest that increased levels of HbA1c may contribute to the progression of NAFLD either directly, by stimulating RAGE or indirectly, through the promotion of hypoxia and suppression of the release of NO. Further studies are needed to test the impact of HbA1c on the development of the chronic liver disease.

scholarly journals RISK FACTORS ASSOCIATED WITH TYPE 2 DIABETES MELLITUS AND THE FREQUENCY OF NAFLD AFFECTED PATIENTS

2021 ◽  
Vol 9 (07) ◽  
pp. 11-15
Author(s):  
Rehana Ahmed ◽  
◽  
Mahrukh Hamed ◽  
Nebela Khan ◽  
Saurabh Singh ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Diabetics have a higher risk of developing nonalcoholic fatty liver disease (NAFLD) and associated complications than the general population. The purpose of this study was to determine the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with type 2 diabetes, as well as the demographic, metabolic, and biochemical features associated with it. Material and methods: This was a prospective, observational, descriptive (cross-sectional), and non-interventional research on a cohort of type 2 diabetes mellitus patients conducted in a hospital setting. Over the course of 18 months, this study was done (August 2019 to March 2021). Results: A total of 100 patients were enrolled, with 63 (63%) being Females and 64 (37%) being men. Age, BMI, and diabetes duration all had statistically significant positive correlations with the prevalence of nonalcoholic fatty liver disease. Overall prevalence of NAFLD was 63 percent (63/100). In this investigation, gender, age > 48, BMI > 25 kg/m2, and diabetes mellitus duration > 10 years were all risk variables linked with the existence of NAFLD (p=0.0002). Conclusion:Present study highlighted the significant burden of Non-Alcoholic Fatty Liver Disease in cohort of type -2 Diabetes Mellitus. About half of the subjects had NAFLD (63%). In present study high BMI, and duration of diabetes > 10 years were positively correlated with NAFLD.

New therapy for fatty liver

2018 ◽  
Vol 1 (2) ◽  
pp. 24-28
Author(s):  
Tanita Suttichaimongkol
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Insulin Resistance ◽  
Alcoholic Fatty Liver Disease ◽  
Related Mortality

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of death from liver cirrhosis, endstage liver disease, and hepatocellular carcinoma. It is also associated with increased cardiovasculardisease and cancer related mortality. While lifestyle modifications are the mainstay of treatment,only a proportion of patients are able to make due to difficult to achieve and maintain, and so moretreatment options are required such as pharmacotherapy. This review presents the drugs used inmanaging NAFLD and their pharmacologic targets. Therapies are currently directed towards improvingthe metabolic status of the liver, insulin resistance, cell oxidative stress, apoptosis, inflammation orfibrosis. Several agents are now in large clinical trials and within the next few years, the availability oftherapeutic options for NAFLD will be approved.     Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, cirrhosis  

Sign in / Sign up

Export Citation Format

Share Document